Cargando…

A Nomogram Predicting Progression Free Survival in Patients with Gastrointestinal Stromal Tumor Receiving Sunitinib: Incorporating Pre-Treatment and Post-Treatment Parameters

SIMPLE SUMMARY: Sunitinib has been approved as the second-line targeted treatment for gastrointestinal stromal tumor (GIST) after imatinib failure. It is thus necessary to effectively assess prognosis after sunitinib use. However, the current assessment remains insufficient for the contemporary peri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Yau-Ren, Huang, Wen-Kuan, Wang, Shang-Yu, Wu, Chiao-En, Chen, Jen-Shi, Yeh, Chun-Nan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197516/ https://www.ncbi.nlm.nih.gov/pubmed/34070456 http://dx.doi.org/10.3390/cancers13112587

Ejemplares similares

Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study()
por: Chen, Yen-Yang, et al.
Publicado: (2014)

Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives
por: Mulet-Margalef, Nuria, et al.
Publicado: (2016)

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges
por: Huang, Wen-Kuan, et al.
Publicado: (2022)

Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non-randomized, single-center study
por: Hu, Chia-Hsiang, et al.
Publicado: (2020)

Pneumatosis Cystoides Intestinalis Secondary to Sunitinib Treatment for Gastrointestinal Stromal Tumor
por: Asahi, Yoh, et al.
Publicado: (2018)

Cytoreductive Surgery may be beneficial for highly selected patients with Metastatic Gastrointestinal Stromal Tumors receiving Regorafenib facing Local Progression: A Case Controlled Study
por: Yeh, Chun-Nan, et al.
Publicado: (2021)

p53 as a biomarker and potential target in gastrointestinal stromal tumors
por: Wu, Chiao-En, et al.
Publicado: (2022)

Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View
por: Wu, Chiao-En, et al.
Publicado: (2019)

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
por: Tielen, Ronald, et al.
Publicado: (2012)

Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study
por: Hsu, Jun-Te, et al.
Publicado: (2017)

Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours
por: SAPONARA, MARISTELLA, et al.
Publicado: (2014)

Sunitinib Treatment for Multiple Brain Metastases from Jejunal Gastrointestinal Stromal Tumor: Case Report
por: TAKEUCHI, Hayato, et al.
Publicado: (2014)

Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors
por: Khosravan, Reza, et al.
Publicado: (2021)

Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series
por: Rutkowski, Piotr, et al.
Publicado: (2017)

A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours
por: Contreras-Hernández, I, et al.
Publicado: (2008)

Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome
por: Wang, Shang-Yu, et al.
Publicado: (2019)

Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
por: Kim, Hyo-Sin, et al.
Publicado: (2014)

Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib
por: Pallotti, Maria Caterina, et al.
Publicado: (2012)

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis
por: Zhang, Zhenan, et al.
Publicado: (2017)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation
por: Brohl, Andrew S., et al.
Publicado: (2015)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Nomogram for predicting survival in patients with advanced hepatocellular carcinoma treated with PD-1 inhibitors: incorporating pre-treatment and post-treatment clinical parameters
por: Jia, Guhe, et al.
Publicado: (2023)

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
por: Reichardt, Peter, et al.
Publicado: (2016)

Digestive tract hemorrhage due to complications with gastrointestinal stromal tumor treated with sunitinib: A case report
por: LIU, YAN, et al.
Publicado: (2013)

Reduction and Escalation in the Dose of Sunitinib Were Adequately Effective against Gastrointestinal Stromal Tumor of the Small Intestine
por: Ogata, Misato, et al.
Publicado: (2019)

Debulking of Advanced Gastrointestinal Stromal Tumor With Peritoneal Carcinomatosis Refractory to Imatinib and Sunitinib: A Case Report
por: Rave, Talia E., et al.
Publicado: (2021)

Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)
por: Le Tourneau, Christophe, et al.
Publicado: (2007)

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
por: Bauer, Sebastian, et al.
Publicado: (2022)

Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor
por: Komatsu, Yoshito, et al.
Publicado: (2015)

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
por: Kang, Y-K, et al.
Publicado: (2013)

Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial
por: Verschuur, Arnauld C., et al.
Publicado: (2019)

Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland
por: Brzozowska, Melania, et al.
Publicado: (2019)

Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-Based Chemotherapy
por: Wu, Chiao-En, et al.
Publicado: (2021)

Radiotherapy in the treatment of gastrointestinal stromal tumor
por: Knowlton, Christin A., et al.
Publicado: (2011)

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
por: Rutkowski, Piotr, et al.
Publicado: (2017)

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
por: Khosravan, Reza, et al.
Publicado: (2016)

Preoperative therapy with sunitinib malate in a patient with a gastrointestinal stromal tumor and liver metastases: A case report
por: Wang, Zhi-Qiang, et al.
Publicado: (2019)

A Nomogram for Predicting Cancer-Specific Survival of Patients with Gastrointestinal Stromal Tumors
por: Liu, Mengmeng, et al.
Publicado: (2020)

Prognostic Nomogram for Gastrointestinal Stromal Tumors after Surgery Based on the SEER Database
por: Sun, Qianhui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7dg5ilcqv31bu8ail7ksimogtl